Sitagliptin 25mg 25mg | Purity Not Available
Adooq Bioscience
Sitagliptin is an oral antihyperglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class.
More Information Supplier PageSearch Results
Sitagliptin 10mM * 1mL in DMSO 10mM * 1mL in DMSO | Purity Not Available
Adooq Bioscience
Sitagliptin is an oral antihyperglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class.
More Information Supplier PageSitagliptin 100mg 100mg | Purity Not Available
Adooq Bioscience
Sitagliptin is an oral antihyperglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class.
More Information Supplier Page(+)PD 128907 5mg 5mg | Purity Not Available
Adooq Bioscience
(+)-PD 128907 hydrochloride is a potent D3DR (dopamine receptor) agonist (Ki = 2.3 nM).
More Information Supplier Page(+)PD 128907 25mg 25mg | Purity Not Available
Adooq Bioscience
(+)-PD 128907 hydrochloride is a potent D3DR (dopamine receptor) agonist (Ki = 2.3 nM).
More Information Supplier Page(+)PD 128907 10mg 10mg | Purity Not Available
Adooq Bioscience
(+)-PD 128907 hydrochloride is a potent D3DR (dopamine receptor) agonist (Ki = 2.3 nM).
More Information Supplier PageTropisetron HCL 500mg 500mg | Purity Not Available
Adooq Bioscience
Tropisetron is a selective 5-HT3 receptor antagonist and ??7-nicotinic receptor agonist with an IC50 of 70.1 ?? 0.9 nM for 5-HT3 receptor.
More Information Supplier PageTropisetron HCL 10mM * 1mL in DMSO 10mM * 1mL in DMSO | Purity Not Available
Adooq Bioscience
Tropisetron is a selective 5-HT3 receptor antagonist and ??7-nicotinic receptor agonist with an IC50 of 70.1 ?? 0.9 nM for 5-HT3 receptor.
More Information Supplier PageTropisetron HCL 100mg 100mg | Purity Not Available
Adooq Bioscience
Tropisetron is a selective 5-HT3 receptor antagonist and ??7-nicotinic receptor agonist with an IC50 of 70.1 ?? 0.9 nM for 5-HT3 receptor.
More Information Supplier PageLuAE58054 10mg 10mg | Purity Not Available
Adooq Bioscience
LuAE58054 is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer’s disease and schizophrenia.
More Information Supplier Page